{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:00:34Z","timestamp":1792504834715,"version":"4.5.0"},"reference-count":93,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a rare but often fatal hyperinflammatory syndrome caused by an inborn or acquired error of immunity. In adults, the underlying immunodeficiency generally arises alongside severe infections, malignancies, autoimmune diseases, and immunosuppressive treatment. To analyze risk factors and outcome in adults, we conducted a multicenter retrospective study. A total of 62 adult (age \u226518 years) patients met at least one of the following inclusion criteria: (1) \u22655 of 8 HLH-2004 criteria, (2) HScore \u2265\u00a0200 plus 4 HLH-2004 criteria, or (3) mutation compatible with an HLH diagnosis. Most patients (65%) were male, and the median age at diagnosis was 53.5 years (range, 19-81 years). All patients were assigned to 4 etiologic subgroups based on their most likely HLH trigger. The survival probability of the 4 etiologic subgroups differed significantly (P\u00a0= .004, log-rank test), with patients with an underlying malignancy having the worst clinical outcome (1-year survival probability of 21%). The parameters older age, malignant trigger, elevated serum levels of aspartate transferase, creatinine, international normalized ratio, lactate dehydrogenase, sCD25, and a low albumin level and platelet count at treatment initiation were significantly (P\u00a0&amp;lt; .1) associated with worse overall survival in the univariate Cox regression model. In multivariate analysis, sCD25 remained the only significant prognostic factor (P\u00a0= .005). Our results suggest that sCD25 could be a useful marker for the prognosis of patients with HLH that might help to stratify therapeutic interventions.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007953","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T16:12:18Z","timestamp":1660666338000},"page":"832-844","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-4753","authenticated-orcid":false,"given":"Thomas","family":"Wimmer","sequence":"first","affiliation":[{"name":"1Department of Medicine III, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-6873","authenticated-orcid":false,"given":"Raphael","family":"Mattes","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-8555","authenticated-orcid":false,"given":"Hans-Joachim","family":"Stemmler","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9644-2003","authenticated-orcid":false,"given":"Fabian","family":"Hauck","sequence":"additional","affiliation":[{"name":"2Division of Pediatric Immunology and Rheumatology, Department of Pediatrics at the Dr. von Hauner Children\u2019s Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[{"name":"3Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-1020","authenticated-orcid":false,"given":"Stephanie-Susanne","family":"Stecher","sequence":"additional","affiliation":[{"name":"4Department of Medicine II, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Starck","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2866-2260","authenticated-orcid":false,"given":"Clemens-Martin","family":"Wendtner","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bojko","sequence":"additional","affiliation":[{"name":"6Department of Medicine III \u2013 Hematology and Oncology, Red Cross Hospital Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-348X","authenticated-orcid":false,"given":"Marcus","family":"Hentrich","sequence":"additional","affiliation":[{"name":"6Department of Medicine III \u2013 Hematology and Oncology, Red Cross Hospital Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4967-9232","authenticated-orcid":false,"given":"Katharina E.","family":"Nickel","sequence":"additional","affiliation":[{"name":"7Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-8002","authenticated-orcid":false,"given":"Katharina S.","family":"G\u00f6tze","sequence":"additional","affiliation":[{"name":"7Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany"},{"name":"8German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-2609","authenticated-orcid":false,"given":"Florian","family":"Bassermann","sequence":"additional","affiliation":[{"name":"7Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany"},{"name":"8German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-052X","authenticated-orcid":false,"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, LMU Munich, Munich, Germany"},{"name":"8German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany"},{"name":"9Nine-i Multinational Research Network, Service de M\u00e9decine Intensive et R\u00e9animaton M\u00e9dicale, H\u00f4pital Saint-Louis, Paris, France"},{"name":"10Intensive Care in Hematologic and Oncologic Patients (iCHOP), Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-4957","authenticated-orcid":false,"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, LMU Munich, Munich, Germany"},{"name":"8German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"issue":"5","key":"2023081515545344200_bib1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1055\/s-0029-1237386","article-title":"Hemophagocytic lymphohistiocytosis: when the immune system runs amok","volume":"221","author":"Janka","year":"2009","journal-title":"Klin P\u00e4diatr"},{"key":"2023081515545344200_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka","year":"2012","journal-title":"Annu Rev Med"},{"issue":"22","key":"2023081515545344200_bib3","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2023081515545344200_bib4","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","article-title":"Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2023081515545344200_bib5","doi-asserted-by":"crossref","first-page":"e44649","DOI":"10.1371\/journal.pone.0044649","article-title":"Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series","volume":"7","author":"Sieni","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2023081515545344200_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MOP.0b013e32834ec9c1","article-title":"Hemophagocytic lymphohistiocytosis: updates and evolving concepts","volume":"24","author":"Risma","year":"2012","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"2023081515545344200_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bjh.14147","article-title":"Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities","volume":"174","author":"Brisse","year":"2016","journal-title":"Br J Haematol"},{"issue":"6047","key":"2023081515545344200_bib8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)61951-7","article-title":"Histiocytic medullary reticulosis","volume":"234","author":"Bodley Scott","year":"1939","journal-title":"Lancet"},{"issue":"136","key":"2023081515545344200_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/adc.27.136.519","article-title":"Familial haemophagocytic reticulosis","volume":"27","author":"Farquhar","year":"1952","journal-title":"Arch Dis Child"},{"issue":"7","key":"2023081515545344200_bib10","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2023081515545344200_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2023081515545344200_bib12","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"17","key":"2023081515545344200_bib13","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2023081515545344200_bib14","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2023081515545344200_bib15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2014-10-602607","article-title":"Marked hyperferritinemia does not predict for HLH in the adult population","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2023081515545344200_bib16","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"issue":"19","key":"2023081515545344200_bib17","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","article-title":"How I treat hemophagocytic lymphohistiocytosis in the adult patient","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2023081515545344200_bib18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003664","article-title":"Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect","volume":"136","author":"Carvelli","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2023081515545344200_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.blre.2014.03.002","article-title":"Hemophagocytic syndromes--an update","volume":"28","author":"Janka","year":"2014","journal-title":"Blood Rev"},{"issue":"6","key":"2023081515545344200_bib20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.blre.2016.05.001","article-title":"Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review","volume":"30","author":"Hayden","year":"2016","journal-title":"Blood Rev"},{"issue":"4","key":"2023081515545344200_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1651-2227.1991.tb11878.x","article-title":"Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis","volume":"80","author":"Henter","year":"1991","journal-title":"Acta Paediatr Scand"},{"issue":"1","key":"2023081515545344200_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1532\/IJH97.07012","article-title":"Nationwide survey of hemophagocytic lymphohistiocytosis in Japan","volume":"86","author":"Ishii","year":"2007","journal-title":"Int J Hematol"},{"issue":"1","key":"2023081515545344200_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s13023-021-01976-1","article-title":"Epidemiological investigation of hemophagocytic lymphohistiocytosis in China","volume":"16","author":"Yao","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2023081515545344200_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/joim.13432","article-title":"Incidence and survival of haemophagocytic lymphohistiocytosis: a population-based cohort study from England","volume":"291","author":"West","year":"2022","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"2023081515545344200_bib25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00432-020-03139-4","article-title":"Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry","volume":"146","author":"Birndt","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"2023081515545344200_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.13102","article-title":"Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide","volume":"168","author":"Arca","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2023081515545344200_bib27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/16078454.2019.1660458","article-title":"Risk factors of early death in adult patients with secondary hemophagocytic lymphohistiocytosis: a single-institution study of\u00a0171 Chinese patients","volume":"24","author":"Zhao","year":"2019","journal-title":"Hematology"},{"issue":"8","key":"2023081515545344200_bib28","first-page":"997","article-title":"Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies","volume":"100","author":"Lehmberg","year":"2015","journal-title":"Haematologica"},{"issue":"5446","key":"2023081515545344200_bib29","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","article-title":"Perforin gene defects in familial hemophagocytic lymphohistiocytosis","volume":"286","author":"Stepp","year":"1999","journal-title":"Science"},{"issue":"4","key":"2023081515545344200_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0092-8674(03)00855-9","article-title":"Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3)","volume":"115","author":"Feldmann","year":"2003","journal-title":"Cell"},{"issue":"12","key":"2023081515545344200_bib31","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1172\/JCI40732","article-title":"Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells","volume":"119","author":"Cote","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2023081515545344200_bib32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ajhg.2009.09.005","article-title":"Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11","volume":"85","author":"zur Stadt","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"7115","key":"2023081515545344200_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature05257","article-title":"XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome","volume":"444","author":"Rigaud","year":"2006","journal-title":"Nature"},{"issue":"7","key":"2023081515545344200_bib34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1182\/blood-2010-01-256099","article-title":"XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease","volume":"116","author":"Marsh","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2023081515545344200_bib35","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2010-07-298372","article-title":"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type 2 (XLP-2\/XIAP deficiency)","volume":"117","author":"Pachlopnik Schmid","year":"2011","journal-title":"Blood"},{"issue":"9927","key":"2023081515545344200_bib36","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"2023081515545344200_bib37","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.amjmed.2014.04.034","article-title":"Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients","volume":"127","author":"Riviere","year":"2014","journal-title":"Am J Med"},{"issue":"6","key":"2023081515545344200_bib38","first-page":"786","article-title":"Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study","volume":"165","author":"Sano","year":"2014","journal-title":"Br\u00a0J\u00a0Haematol"},{"issue":"22","key":"2023081515545344200_bib39","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood.V128.22.5991.5991","article-title":"Adult lymphoma-associated hemophagocytic syndrome is a life-threatening disease: retrospective 10-year review of 89 cases at a single center","volume":"128","author":"Jin","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2023081515545344200_bib40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/10245332.2017.1385191","article-title":"Multivariate analysis of prognosis for patients with natural killer\/T cell lymphoma-associated hemophagocytic lymphohistiocytosis","volume":"23","author":"Jin","year":"2018","journal-title":"Hematology"},{"issue":"6","key":"2023081515545344200_bib41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.transci.2018.10.001","article-title":"What\u2019s in a name? The heterogeneous clinical spectrum and prognostic factors in a cohort of adults with\u00a0hemophagocytic lymphohistiocytosis","volume":"57","author":"Prokesch","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"2023081515545344200_bib42","doi-asserted-by":"crossref","first-page":"788056","DOI":"10.3389\/fonc.2021.788056","article-title":"Clinical features and prognostic risk prediction of non-hodgkin lymphoma-associated hemophagocytic syndrome","volume":"11","author":"Yao","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"2023081515545344200_bib43","first-page":"484","article-title":"Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis","volume":"89","author":"Parikh","year":"2014","journal-title":"Mayo\u00a0Clin Proc"},{"issue":"3","key":"2023081515545344200_bib44","first-page":"220","article-title":"Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis","volume":"90","author":"Otrock","year":"2015","journal-title":"Am\u00a0J\u00a0Hematol"},{"issue":"3","key":"2023081515545344200_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.13837","article-title":"Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years","volume":"172","author":"Schram","year":"2016","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2023081515545344200_bib46","first-page":"5205","article-title":"Clinical characteristics and outcomes of hemophagocytic lymphohistiocytosis-associated lymphoma: a case-control study","volume":"130","author":"Apodaca","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023081515545344200_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatology"},{"issue":"12","key":"2023081515545344200_bib48","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/ard.2005.046904","article-title":"Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature","volume":"65","author":"Arlet","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2023081515545344200_bib49","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/rheumatology\/ken342","article-title":"Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of\u00a030\u00a0cases","volume":"47","author":"Fukaya","year":"2008","journal-title":"Rheumatology"},{"issue":"1","key":"2023081515545344200_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MD.0b013e3181caf100","article-title":"Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a\u00a0case-control study of 8 patients","volume":"89","author":"Hot","year":"2010","journal-title":"Medicine (Baltim)"},{"issue":"11","key":"2023081515545344200_bib51","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/rheumatology\/keh710","article-title":"Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?","volume":"44","author":"Ramanan","year":"2005","journal-title":"Rheumatology"},{"issue":"5","key":"2023081515545344200_bib52","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"2023081515545344200_bib53","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10067-014-2487-4","article-title":"Life-threatening complications of adult-onset Still's disease","volume":"33","author":"Efthimiou","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2023081515545344200_bib54","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"10","key":"2023081515545344200_bib55","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2001.19.10.2665","article-title":"Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis","volume":"19","author":"Imashuku","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023081515545344200_bib56","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023081515545344200_bib57","first-page":"654","article-title":"Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series","volume":"106","author":"Hansen","year":"2021","journal-title":"Eur\u00a0J\u00a0Haematol"},{"issue":"4","key":"2023081515545344200_bib58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"2023081515545344200_bib59","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A\u00a0study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2023081515545344200_bib60","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-017-2993-y","article-title":"Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review","volume":"96","author":"Lin","year":"2017","journal-title":"Ann Hematol"},{"issue":"5","key":"2023081515545344200_bib61","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jpeds.2013.06.053","article-title":"Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment","volume":"163","author":"Chandrakasan","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"26","key":"2023081515545344200_bib62","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/bloodadvances.2017012310","article-title":"Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH","volume":"1","author":"Hayden","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"2023081515545344200_bib63","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00277-020-04083-6","article-title":"A\u00a0comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study","volume":"99","author":"Yoon","year":"2020","journal-title":"Ann Hematol"},{"issue":"4","key":"2023081515545344200_bib64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10428199109107916","article-title":"Serum levels of interferon-gamma, cytotoxic factor and soluble interleukin-2 receptor in childhood hemophagocytic syndromes","volume":"3","author":"Imashuku","year":"1991","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2023081515545344200_bib65","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood.V86.12.4706.bloodjournal86124706","article-title":"Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis","volume":"86","author":"Imashuku","year":"1995","journal-title":"Blood"},{"issue":"2","key":"2023081515545344200_bib66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MD.0000000000000022","article-title":"Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients","volume":"93","author":"Li","year":"2014","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"2023081515545344200_bib67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13023-020-1336-6","article-title":"Development and validation of the prognostic value of ferritin in adult patients with hemophagocytic lymphohistiocytosis","volume":"15","author":"Zhou","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2023081515545344200_bib68","doi-asserted-by":"crossref","first-page":"108515","DOI":"10.1016\/j.clim.2020.108515","article-title":"The IL-2 - IL-2 receptor pathway in health and disease: the role of the soluble IL-2 receptor","volume":"218","author":"Damoiseaux","year":"2020","journal-title":"Clin Immunol"},{"issue":"7","key":"2023081515545344200_bib69","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3109\/10428194.2011.566394","article-title":"Significance of soluble interleukin-2 receptor in patients with hemophagocytic lymphohistiocytosis","volume":"52","author":"Zhang","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2023081515545344200_bib70","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2023081515545344200_bib71","doi-asserted-by":"crossref","first-page":"e7980","DOI":"10.1371\/journal.pone.0007980","article-title":"Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation","volume":"4","author":"Brusko","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"2023081515545344200_bib72","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2023081515545344200_bib73","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2010-12-324533","article-title":"Perforin is a critical physiologic regulator of T-cell activation","volume":"118","author":"Lykens","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2023081515545344200_bib74","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2023081515545344200_bib75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2023081515545344200_bib76","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1542\/peds.2006-3164","article-title":"Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients","volume":"120","author":"Mahlaoui","year":"2007","journal-title":"Pediatrics"},{"issue":"2","key":"2023081515545344200_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/pbc.24039","article-title":"Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis","volume":"59","author":"Shiraishi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2023081515545344200_bib78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mpo.1294","article-title":"Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis","volume":"38","author":"Tomaske","year":"2002","journal-title":"Med Pediatr Oncol"},{"issue":"9","key":"2023081515545344200_bib79","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ajh.21236","article-title":"Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis","volume":"83","author":"Olin","year":"2008","journal-title":"Am J Hematol"},{"issue":"2","key":"2023081515545344200_bib80","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3324\/haematol.2018.198655","article-title":"Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy","volume":"104","author":"Yoon","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"2023081515545344200_bib81","first-page":"2181","article-title":"Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis","volume":"100","author":"Lu","year":"2021","journal-title":"Ann\u00a0Hematol"},{"issue":"10","key":"2023081515545344200_bib82","first-page":"1548","article-title":"Hyperferritinemia in adult HLH: the best what we have, so far","volume":"125","author":"Machowicz","year":"2015","journal-title":"Blood [e-Letter]"},{"issue":"1","key":"2023081515545344200_bib83","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajh.1141","article-title":"Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes","volume":"68","author":"Emmenegger","year":"2001","journal-title":"Am J Hematol"},{"issue":"3","key":"2023081515545344200_bib84","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjh.12138","article-title":"Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis","volume":"160","author":"Lehmberg","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2023081515545344200_bib85","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1097\/MPH.0b013e31824227b9","article-title":"Serum ferritin is a cost-effective laboratory marker for hemophagocytic lymphohistiocytosis in the developing world","volume":"34","author":"Switala","year":"2012","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"6","key":"2023081515545344200_bib86","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10067-013-2227-1","article-title":"Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review","volume":"32","author":"Vilaiyuk","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2023081515545344200_bib87","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pbc.22774","article-title":"Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality","volume":"56","author":"Lin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2023081515545344200_bib88","first-page":"1024","article-title":"Increasing ferritin predicts early death in adult hemophagocytic lymphohistiocytosis","volume":"43","author":"Abou Shaar","year":"2021","journal-title":"Int\u00a0J\u00a0Lab Hematol"},{"issue":"1","key":"2023081515545344200_bib89","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/07853890.2022.2027513","article-title":"Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy","volume":"54","author":"Hua","year":"2022","journal-title":"Ann Med"},{"issue":"7","key":"2023081515545344200_bib90","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.2021012764","article-title":"An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023081515545344200_bib91","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1080\/10428194.2016.1195498","article-title":"The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma","volume":"57","author":"Tomita","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023081515545344200_bib92","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-01-757542","article-title":"Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma","volume":"130","author":"Katsuya","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023081515545344200_bib93","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000\u00a0and 2013: a cooperative study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/5\/832\/2071323\/blooda_adv-2022-007953-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/5\/832\/2071323\/blooda_adv-2022-007953-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T12:06:15Z","timestamp":1692101175000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/5\/832\/486252\/sCD25-as-an-independent-adverse-prognostic-factor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007953","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}